David Goldstein - Researcher Profile

Publications

2 shown

Erlotinib Plus Gemcitabine Compared With Gemcitabine Alone in Patients With Advanced Pancreatic Cancer: A Phase III Trial of the National Cancer Institute of Canada Clinical Trials Group

Malcolm J. Moore , David Goldstein , John Hamm +14 more

Purpose Patients with advanced pancreatic cancer have a poor prognosis and there have been no improvements in survival since the introduction of gemcitabine in 1996. Pancreatic ...

2007 Journal of Clinical Oncology 3833 citations

Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial

Kohei Shitara , Mustafa Özgüroğlu , Yung‐Jue Bang +97 more

2018 The Lancet 1262 citations

Frequent Co-Authors

Researcher Info

h-index: 2
Publications: 2
Citations: 5,095
Institution: Princess Margaret Cancer Centre

External Links

ORCID Profile Google Scholar

Identifiers

ORCID: 0000-0001-6142-3291

Impact Metrics

h-index 2

h-index: Number of publications with at least h citations each.